Skip to content

Current Pharmaceutical Design

ISSN 1381-6128

18 papers in the library · 441 citations · publishing 2002-2026

Papers

Sort Most recent Most cited

Therapeutic Potential of Ketamine in Major Depressive Disorder: Pharmacological Insights and Clinical Evidence

Current Pharmaceutical Design July 31, 2026 Prachi Tayal, Rina Das, M.U. Khan et al.

BACKGROUND: Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy. About onethird of patients suffer from treatment-resistant depression (TRD), which emphasizes the urgent need for alternative therapies. This review aims to systematically evaluate the available data about...

Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.

Current Pharmaceutical Design February 28, 2025 Mei Ding, Ping Pei, Weihua Liu et al. 3 citations

As a heterogeneous clinical syndrome, acute respiratory distress syndrome (ARDS) is caused by infection-associated inflammation with limited treatment options. Esketamine possesses antiinflammatory properties, and it is effective in treating lung diseases. This study aimed to unveil the efficacy and mechanism of esketamine in ARDS. Lipopolysaccharide (LPS) is widely used to induce inflammatory...

DOI: 10.2174/0113816128361112250221065359 (opens in new tab) Full text (opens in new tab) Ulk1/fundc1 signaling pathway Mitophagy. Acute lung injury Respiratory failure +4

Vaporized Delta-9-tetrahydrocannabinol Inhalation in Female Sprague Dawley Rats: A Pharmacokinetic and Behavioral Assessment.

Current Pharmaceutical Design 2023 Samantha L Penman, Erin C. Berthold, Abrianna Mihalkovic et al.

Delta-9-tetrahydrocannabinol (THC) is the main psychoactive component of cannabis. Historically, rodent studies examining the effects of THC have used intraperitoneal injection as the route of administration, heavily focusing on male subjects. However, human cannabis use is often through inhalation rather than injection. We sought to characterize the pharmacokinetic and phenotypic profile of...

DOI: 10.2174/1381612829666230419093809 (opens in new tab) Full text (opens in new tab) Cannabis Delta-9-Tetrahydrocannabinol THC Liquid-chromatography/mass-spectrometry Locomotor activity. +2

Ketamine: from prescription anaesthetic to New Psychoactive Substance.

Current Pharmaceutical Design May 10, 2022 M. R. Varı̀, G. Ricci, Marco Cavallo et al.

Discovered in the United States of America (USA) in the 1960s, ketamine was introduced as an anaesthetic drug to specifically replace phencyclidine. Briefly, the substance moved from the medical world to recreational users, since it was discovered that intense psychedelic experiences were obtained with dosages lower than those prescribed for anesthesia. At the end of the 90's, circulated in...

Rapid-Acting Antidepressants

Current Pharmaceutical Design October 19, 2018 Jeffrey M. Witkin, Daniel E. Knutson, Gabriel J. Rodriguez et al. 44 citations

Background: Conventional antidepressants are thought to produce their impact on clinical symptoms by increasing the central availability of biogenic amine neurotransmitters (the monoamine hypothesis of depression). These drugs continue to be the primary medicines used in major depressive disorder. Although they have biological effects after acute dosing, full antidepressant response generally...

DOI: 10.2174/1381612824666180730104707 (opens in new tab) Pharmacology Intensive care medicine

Pharmacology and Literature Review Based on Related Death and Non-Fatal Case Reports of the Benzofurans and Benzodifurans Designer Drugs.

Current Pharmaceutical Design 2017 Bernardino Barcelo, Isabel Gomila

Benzofurans and benzodifurans are two groups of psychoactive substances that had originally been synthesized for research purpose. Benzofurans' structure is quite similar to the known recreational drug 3,4-methylenedioxymethamphetamine together with its active metabolite 3,4-methylenedioxyamphetamine. Benzodifurans are closely related to phenethylamines, but have more hallucinogens effects and...

DOI: 10.2174/1381612823666170714155140 (opens in new tab) Full text (opens in new tab) Benzofurans Benzodifurans New psychoactive substances Pharmacology +2

Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings

Current Pharmaceutical Design May 10, 2014 Johannes Wrege, André Schmidt, Anna Walter et al. 96 citations

We conducted a systematic review to assess the evidence for specific effects of cannabis on impulsivity, disinhibition and motor control. The review had a specific focus on neuroimaging findings associated with acute and chronic use of the drug and covers literature published up until May 2012. Seventeen studies were identified, of which 13 met the inclusion criteria; three studies investigated...

DOI: 10.2174/13816128113199990428 (opens in new tab) Cannabidiol Impulsivity Neuroimaging Disinhibition +2

Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.

Current Pharmaceutical Design 2014 Albert Batalla, José A. Crippa, Geraldo F. Busatto et al.

In recent years, growing concerns about the effects of cannabis use on mental health have renewed interest in cannabis research. In particular, there has been a marked increase in the number of neuroimaging studies of the effects of cannabinoids. We conducted a systematic review to assess the impact of acute cannabis exposure on brain function in humans and in experimental animals. Papers...

The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.

Current Pharmaceutical Design 2014 Lakshmi Rajagopal, Bill W Massey, Mei Huang et al.

Novel object recognition (NOR) in rodents is analogous in some ways to human declarative (episodic) memory, one of the seven cognitive domains which are abnormal in schizophrenia. Cognitive impairment in schizophrenia (CIS) accounts for the largest proportion of the poor functional outcomes in this complex syndrome, with psychosis and negative symptoms accounting for much of the rest. Current...

Harnessing anesthesia and brain imaging for the study of human consciousness.

Current Pharmaceutical Design 2014 Jaakko Långsjö, Antti Revonsuo, Harry Scheinin

Philosophers have been trying to solve the mind-body problem for hundreds of years. Consciousness is the core of this problem: How do subjective conscious sensations, perceptions, feelings, and thoughts arise out of objective physical brain activities? How is this subjective conscious world in causal interaction with the objective sensory and motor mechanisms of the brain and the body? Although...

DOI: 10.2174/13816128113196660650 (opens in new tab) Full text (opens in new tab) Brain Humans Diagnostic imaging Positron-emission tomography +3

Effects of cannabis on the adolescent brain.

Current Pharmaceutical Design 2014 Joanna Jacobus, Susan F Tapert

This article reviews neuroimaging, neurocognitive, and preclinical findings on the effects of cannabis on the adolescent brain. Marijuana is the second most widely used intoxicant in adolescence, and teens who engage in heavy marijuana use often show disadvantages in neurocognitive performance, macrostructural and microstructural brain development, and alterations in brain functioning. It...

The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature.

Current Pharmaceutical Design 2014 Valentina Lorenzetti, Nadia Solowij, Alex Fornito et al.

Cannabis is the most widely used illicit drug worldwide, though it is unclear whether its regular use is associated with persistent alterations in brain morphology. This review examines evidence from human structural neuroimaging investigations of regular cannabis users and focuses on achieving three main objectives. These include examining whether the literature to date provides evidence that...

Modulation of 3,4-methylenedioxymethamphetamine effects by endocannabinoid system.

Current Pharmaceutical Design 2013 Olga Valverde, Marta Rodríguez‐arias

The amphetamine derivative 3, 4 Methylenedioxymethanphetamine (MDMA) is a powerful central nervous system stimulant that displays numerous pharmacological effects, including neurotoxicity. MDMA, or ecstasy, acts by inducing the release of different neurotransmitters depending on the animal species and, in particular, it produces the release of serotonin and dopamine. MDMA induces rewarding and...

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Current Pharmaceutical Design September 12, 2012 Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al. 288 citations

RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...

Patient’s Perceptions of the Cannabis-psychosis Link - A Systematic Review

Current Pharmaceutical Design September 12, 2012 Anna Buadze, Stefan Kaiser, Rudolf Stohler et al. 10 citations

Over the past years a growing research effort has investigated the relation between cannabis use and schizophrenia at a neurobiological, epidemiological and clinical level. A number of systematic reviews and meta analyses have summarized the available evidence in the field. Conversely the patient's perception of the link between cannabis use and psychosis has been under investigation. Since...

Resting state abnormalities in psychosis compared to acute cannabinoids and opioids challenges: a systematic review of functional imaging studies.

Current Pharmaceutical Design 2012 Niklaus Denier, Marc Walter, Kerstin Bendfeldt et al.

We conducted a systematic review on resting state cerebral blood flow activities found in first-episode psychosis (FEP) and during acute effects of cannabinoids and opioids, mental states that can be profoundly different from normal functioning. The main goal was to identify connections of cerebral blood flow measure and regional brain activity patterns associated with subjective experiences...

Microdosing, imaging biomarkers and SPECT: a multi-sided tripod to accelerate drug development.

Current Pharmaceutical Design 2009 Ernest K J Pauwels, Kim Bergstrom, Giuliano Mariani et al.

The advances of nuclear medicine imaging instrumentation and radiopharmaceutical sciences allow their involvement in the developmental processes of therapeutic drugs. New chemical entities, meant as potential drugs, need to comply with the proof-of-principle. Tomographic imaging methods as PET, SPECT and CT have been used for small animal and human studies at an early stage of drug development....

Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia.

Current Pharmaceutical Design 2002 Chihiro Ito

Although the etiology of drug psychosis or schizophrenia is still unknown, molecular and biochemical researches have recently made significant advances in the search for the candidate genes of these disorders. Among such studies are animal models of drug psychosis or schizophrenia such as amphetamine-induced behavioral sensitization or phencyclidine-treated animals. In this review, it is...